What is HC Wainwright’s Forecast for ABOS FY2029 Earnings?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Acumen Pharmaceuticals in a report issued on Friday, March 28th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($2.03) per share for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

Separately, UBS Group reduced their price objective on shares of Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, March 28th.

Acumen Pharmaceuticals Stock Performance

ABOS stock opened at $1.08 on Monday. The firm has a 50 day moving average of $1.35 and a two-hundred day moving average of $1.96. Acumen Pharmaceuticals has a 12 month low of $1.06 and a 12 month high of $4.06. The company has a market capitalization of $64.59 million, a price-to-earnings ratio of -0.78 and a beta of 0.02. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.14.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.15).

Insider Activity at Acumen Pharmaceuticals

In other Acumen Pharmaceuticals news, CFO Matt Zuga sold 28,902 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $1.72, for a total transaction of $49,711.44. Following the completion of the transaction, the chief financial officer now owns 231,744 shares of the company’s stock, valued at $398,599.68. The trade was a 11.09 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $87,911.52. Following the sale, the chief executive officer now owns 454,707 shares of the company’s stock, valued at $836,660.88. This trade represents a 9.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 131,526 shares of company stock valued at $233,124. Corporate insiders own 7.10% of the company’s stock.

Hedge Funds Weigh In On Acumen Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC acquired a new stake in Acumen Pharmaceuticals in the 4th quarter valued at approximately $25,000. Clune & Associates LTD. bought a new stake in shares of Acumen Pharmaceuticals in the fourth quarter valued at approximately $28,000. Intech Investment Management LLC acquired a new stake in shares of Acumen Pharmaceuticals in the fourth quarter worth $32,000. Tower Research Capital LLC TRC increased its position in Acumen Pharmaceuticals by 427.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company’s stock worth $35,000 after acquiring an additional 16,714 shares during the period. Finally, SG Americas Securities LLC raised its stake in Acumen Pharmaceuticals by 44.2% during the 4th quarter. SG Americas Securities LLC now owns 25,631 shares of the company’s stock valued at $44,000 after purchasing an additional 7,859 shares during the last quarter. Institutional investors and hedge funds own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.